Cargando…

Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells

Src and the mammalian target of rapamycin (mTOR) signaling are commonly activated in non-small cell lung cancer (NSCLC) and hence potential targets for chemotherapy. Although the combined use of Src inhibitor Dasatinib with other chemotherapeutic agents has shown superior efficacy for cancer treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Bin, Xu, Xin, Luo, Jie, Wang, Heyong, Zhou, Songwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465694/ https://www.ncbi.nlm.nih.gov/pubmed/26061184 http://dx.doi.org/10.1371/journal.pone.0129663

Ejemplares similares

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021)

Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer
por: Liu, Tao, et al.
Publicado: (2021)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023)

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020)

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
por: Elfiky, Aymen A, et al.
Publicado: (2011)

Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
por: Wu, Yukun, et al.
Publicado: (2019)

Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
por: Yoon, Mee-Sup
Publicado: (2017)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
por: Lawrence, Jessica, et al.
Publicado: (2018)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity
por: HAN, XIAO, et al.
Publicado: (2014)

Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway
por: Mickymaray, Suresh, et al.
Publicado: (2021)

Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway
por: Liu, Bin, et al.
Publicado: (2018)

Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway
por: Barclay, Robert A., et al.
Publicado: (2020)

Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway
por: Wang, Bin, et al.
Publicado: (2020)

TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis
por: Zhao, Guo-sheng, et al.
Publicado: (2018)

Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer
por: Cao, Guo-dong, et al.
Publicado: (2016)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways
por: Liang, Guanzhao, et al.
Publicado: (2017)

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer
por: Scott, Kenneth L., et al.
Publicado: (2009)

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
por: Seto, Belinda
Publicado: (2012)

mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain
por: Yang, Haijuan, et al.
Publicado: (2013)

Brain size is controlled by the mammalian target of rapamycin (mTOR) in mice
por: Kim, Woo-Yang
Publicado: (2015)

The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
por: Maiese, Kenneth
Publicado: (2020)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
por: Zhao, Wei, et al.
Publicado: (2023)

PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
por: Cheng, Zhi Y, et al.
Publicado: (2008)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy
por: Yu, Chune, et al.
Publicado: (2020)

Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
por: Choi, Dong hyuck, et al.
Publicado: (2019)

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
por: Gotesman, Moran, et al.
Publicado: (2018)

SH2B1 promotes NSCLC cell proliferation through PI3K/Akt/mTOR signaling cascade
por: Wang, Shaoqiang, et al.
Publicado: (2018)

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
por: Colombo, Marika, et al.
Publicado: (2022)

Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
por: Gargalionis, Antonios N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lunajcu1ivpmcgdgnju4qn8c9a